Department of Virology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran.
Biomed Res Int. 2021 Sep 18;2021:9294276. doi: 10.1155/2021/9294276. eCollection 2021.
Knowledge regarding the prevalence and risk factors of hepatitis C virus (HCV) infection among pregnant women can give clue to health care providers regarding the appropriate management of HCV infection. Therefore, this study was conducted to determine the prevalence, genotypic pattern, and risk factors of HCV infection among pregnant women in the northern shores of the Persian Gulf, south of Iran.
From January 2018 to June 2019, serum samples were obtained from 1425 pregnant women, ages ranging from 14 to 46 years (28.1 ± 5.99). Serum samples were tested for detection of anti-HCV antibodies using an enzyme-linked immunosorbent assay (ELISA) (HCV Ab ELISA kit, Dia.Pro, Milan, Italy). Following the extraction of nucleic acid, the molecular evaluation of HCV infection was performed by seminested reverse transcriptase-polymerase chain reaction assay (RT-PCR), targeting the 5' untranslated region (5'UTR) and core of HCV genome and sequencing.
Of the 1425 pregnant women, 19 women (1.33%, 95% CI: 0.85%-2.07%) were positive for anti-HCV antibodies. The majority of HCV-seropositive women were in the third trimester of pregnancy, educated, and had a history of blood transfusion, abortion, surgery, or dentistry. Moreover, Arab and Fars pregnant women and those aged >39 years had the highest rate of HCV seroprevalence. Nevertheless, none of these variables were significantly associated with HCV seropositivity. In contrast, HCV seropositivity was associated with place of residency, so that residents of Khormuj city had significantly higher HCV seroprevalence compared to the residents of other cities (OR: 7.05; 95% CI: 1.75-28.39; = 0.006). According to the molecular evaluation, 9 of the 19 HCV-seropositive pregnant women (47.37%) had HCV viremia with genotype 3a.
This study reports the HCV prevalence of 1.33% for anti-HCV antibodies and 0.63% for HCV RNA among pregnant women in the south of Iran. Considering the asymptomatic nature of chronic HCV infection and the fact that vertical transmission is possible in women with detectable viremia, therefore, screening of women before pregnancy is recommended to reduce the risk of HCV infection and its complications during pregnancy.
了解孕妇丙型肝炎病毒(HCV)感染的流行率和危险因素,可为医护人员提供 HCV 感染的适当管理线索。因此,本研究旨在确定伊朗南部波斯湾北部孕妇 HCV 感染的流行率、基因型模式和危险因素。
2018 年 1 月至 2019 年 6 月,从 1425 名年龄在 14 至 46 岁(28.1±5.99)的孕妇中抽取血清样本。使用酶联免疫吸附试验(ELISA)(HCV Ab ELISA 试剂盒,Milan,意大利 Dia.Pro)检测血清样本中抗 HCV 抗体的存在。提取核酸后,通过半巢式逆转录聚合酶链反应(RT-PCR)检测 HCV 感染的分子情况,靶向 HCV 基因组的 5'非翻译区(5'UTR)和核心区,并进行测序。
在 1425 名孕妇中,有 19 名(1.33%,95%CI:0.85%-2.07%)抗 HCV 抗体阳性。大多数 HCV 血清阳性的孕妇处于妊娠晚期,受过教育,有输血、流产、手术或牙科治疗史。此外,阿拉伯和法尔斯族孕妇以及年龄>39 岁的孕妇 HCV 血清阳性率最高。然而,这些变量均与 HCV 血清阳性无显著相关性。相反,HCV 血清阳性与居住地有关,与其他城市的居民相比,霍尔木兹市的居民 HCV 血清阳性率显著更高(OR:7.05;95%CI:1.75-28.39;=0.006)。根据分子评估,19 名 HCV 血清阳性孕妇中有 9 名(47.37%)存在 HCV 病毒血症,基因型为 3a。
本研究报告了伊朗南部孕妇 HCV 抗体流行率为 1.33%,HCV RNA 流行率为 0.63%。鉴于慢性 HCV 感染无症状的性质以及可检测到病毒血症的女性垂直传播的可能性,因此建议在妊娠前对女性进行筛查,以降低 HCV 感染及其在妊娠期间并发症的风险。